Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative medicines for serious medical conditions. Founded in 1988, it specializes in monoclonal antibody technologies and has a broad pipeline targeting areas such as ophthalmology, oncology, immunology, and infectious diseases. Known for its collaborations and investment in scientific research, Regeneron has contributed significantly to the development of treatments for various diseases.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 3, 2025 | $0.88 | 2025-08-18 | 2025-08-18 |
| June 6, 2025 | $0.88 | 2025-05-20 | 2025-05-20 |
| March 20, 2025 | $0.88 | 2025-02-20 | 2025-02-20 |
Dividends Summary
- Regeneron Pharmaceuticals Inc has issued 3 dividend payments over the past 0 years
- The most recent dividend was paid 17 days ago, on September 3, 2025
- The highest dividend payed out to investors during this period was $0.88 per share
- The average dividend paid during this period was $0.88 per share.
Company News
The cancer immunotherapy market is projected to reach $258.22 billion by 2031, driven by breakthrough treatments and FDA fast-track approvals. Multiple companies are developing innovative immunotherapies targeting various cancer types with promising clinical trial results.
The biotech sector shows potential for significant growth by year-end, driven by anticipated Federal Reserve rate cuts and improving market conditions that could benefit rate-sensitive biotech stocks.
Law firm investigating Regeneron Pharmaceuticals for potential securities fraud related to misleading statements about Eylea drug sales and credit card fee practices, following DOJ complaint and stock price declines.
Despite facing challenges like tariffs and competition, Intuitive Surgical and Regeneron Pharmaceuticals show promising long-term investment potential due to strong market positioning, innovative products, and growth opportunities.
Regeneron Pharmaceuticals reported better-than-expected Q2 results, driven by growth in Eylea HD, Dupixent, and Libtayo. However, Eylea sales declined due to increased competition. The company's pipeline progress was mixed, with a delay in the FDA decision for linvoseltamab and a three-month extension for the Dupixent COPD indication.
